Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/20/2026, 12:00:00 AM
Biogen and partner Eisai presented new real-world data on March 20, 2026, at the AD/PD™ 2026 conference, showing high long-term treatment persistence for Leqembi, with 67.3% of patients remaining on therapy at 24 months. This event is estimated to have a low impact as it reinforces existing clinical data.
Korean Translation
2026년 3월 20일, 바이오젠과 파트너사 에자이는 AD/PD™ 2026 컨퍼런스에서 레켐비의 높은 장기 치료 지속성을 보여주는 새로운 실제 임상 근거(real-world data)를 발표했으며, 24개월 시점에 환자의 67.3%가 치료를 유지함. 기존 데이터 강화 수준으로 낮은 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM